Gene Disease Score gda Association Type Original DB Sentence supporting the association PMID PMID Year
Entrez Id: 3439
Gene Symbol: IFNA1
IFNA1
CUI: C0019196
Disease: Hepatitis C
Hepatitis C
0.100 AlteredExpression BEFREE Expression of the IFN receptor in hepatocytes may be directly associated with a hepatitis C virus (HCV) infection and the response to IFN therapy. 9783688

1998

Entrez Id: 3439
Gene Symbol: IFNA1
IFNA1
CUI: C0019196
Disease: Hepatitis C
Hepatitis C
0.100 Biomarker BEFREE The decision to stop the therapy in genotype 1 chronic hepatitis C patients treated with PEG-IFN-α-2a and ribavirin can be confidently made after 4 weeks of treatment based on the absence of baseline anti-NS4a Ab and a week-4 hepatitis C virus-RNA above 100.000 IU/ml. 21389795

2010

Entrez Id: 3439
Gene Symbol: IFNA1
IFNA1
CUI: C0019196
Disease: Hepatitis C
Hepatitis C
0.100 GeneticVariation BEFREE A substantial proportion of patients infected with hepatitis C virus (HCV) genotype 1 still does not respond to pegylated interferon-alfa/ribavirin (IFN/RBV) therapy. 14645325

2004

Entrez Id: 3439
Gene Symbol: IFNA1
IFNA1
CUI: C0019196
Disease: Hepatitis C
Hepatitis C
0.100 Biomarker BEFREE The role of IFNs in LX-2 cell-mediated anti-HCV activity is further supported by the observation that LX-2 SN treatment induced the expression of IFN stimulated genes, 2'-5'-oligoadenylate synthase-1 (OAS-1) and myxovirus resistance A (MxA), in HCV-infected Huh7 cells. 23060457

2013

Entrez Id: 3439
Gene Symbol: IFNA1
IFNA1
CUI: C0019196
Disease: Hepatitis C
Hepatitis C
0.100 Biomarker BEFREE The role of the hepatitis C virus (HCV) NS3/4A protease in ablating the signaling pathway involved in the production of alpha/beta interferon (IFN-α/β) suggests a relationship between NS3/4A proteolytic activity and a patient's response to IFN-based therapy. 21471227

2011

Entrez Id: 3439
Gene Symbol: IFNA1
IFNA1
CUI: C0019196
Disease: Hepatitis C
Hepatitis C
0.100 Biomarker BEFREE This open-label, phase IIa study included 10 patients with chronic HCV genotype 1b infection and previous null response (<2 log(10) reduction in HCV RNA after 12 weeks) to Peg-IFN and RBV. 21987462

2012

Entrez Id: 3439
Gene Symbol: IFNA1
IFNA1
CUI: C0019196
Disease: Hepatitis C
Hepatitis C
0.100 Biomarker BEFREE However, these factors only partly explain the ability of IFN and ribavirin therapy to cure HCV infection. 21742299

2011

Entrez Id: 3439
Gene Symbol: IFNA1
IFNA1
CUI: C0019196
Disease: Hepatitis C
Hepatitis C
0.100 GeneticVariation BEFREE This same variant is associated with treatment-induced clearance in patients with genotype 1b, but not 2a. ss469415590 (or rs12979860) genotyping should be considered for patients with HCV genotype 1b and high viral load when making a choice between standard dual therapy and an IFN-free direct-acting antiviral regimen. 26820907

2016

Entrez Id: 3439
Gene Symbol: IFNA1
IFNA1
CUI: C0019196
Disease: Hepatitis C
Hepatitis C
0.100 Biomarker BEFREE From the introduction of interferon (IFN)-α monotherapy in the early 1990s to the approval of telaprevir- and boceprevir-based triple therapies with pegylated (PEG)-IFN-α and ribavirin (RBV) in 2011, the chances of curing patients infected with HCV genotype 1 have improved dramatically to reach approximately 70%. 26159282

2015

Entrez Id: 3439
Gene Symbol: IFNA1
IFNA1
CUI: C0019196
Disease: Hepatitis C
Hepatitis C
0.100 GeneticVariation BEFREE We undertook a longitudinal prospective study of 33 individuals with chronic HCV treated with combination pegylated IFN-α, ribavirin, and telaprevir/boceprevir. 29263212

2018

Entrez Id: 3439
Gene Symbol: IFNA1
IFNA1
CUI: C0019196
Disease: Hepatitis C
Hepatitis C
0.100 AlteredExpression BEFREE DAA treatment of HCV-infected PHHs reduced the expression of IFN-λs, including IFN-λ4, and restored IFN-α responsiveness. 28630501

2017

Entrez Id: 3439
Gene Symbol: IFNA1
IFNA1
CUI: C0019196
Disease: Hepatitis C
Hepatitis C
0.100 Biomarker BEFREE Here we review the different ways that HCV evades the immune response elicited by IFN. 19482597

2009

Entrez Id: 3439
Gene Symbol: IFNA1
IFNA1
CUI: C0019196
Disease: Hepatitis C
Hepatitis C
0.100 Biomarker BEFREE The findings suggest that measuring HCV RNA in serum before and soon after beginning treatment can be helpful for selecting patients who are most likely to have a sustained complete response to standard schedule of alpha-IFN and for identifying patients in whom alternative strategies should be examined. 9496364

1998

Entrez Id: 3439
Gene Symbol: IFNA1
IFNA1
CUI: C0019196
Disease: Hepatitis C
Hepatitis C
0.100 Biomarker BEFREE Our results suggest that HCV G3a along with immune responses such as cytokines in HCV patients should be taken into account when interpreting clinical data and IFN-based therapeutic response. 29147974

2018

Entrez Id: 3439
Gene Symbol: IFNA1
IFNA1
CUI: C0019196
Disease: Hepatitis C
Hepatitis C
0.100 GeneticVariation BEFREE Peptides spanning the modified regions were tested in T cell proliferation assays and found to be less immunogenic than native controls when using peripheral blood mononuclear cells (PBMCs) from both healthy individuals and HCV-infected patients who had been treated previously with IFN-alpha2b. 15450132

2004

Entrez Id: 3439
Gene Symbol: IFNA1
IFNA1
CUI: C0019196
Disease: Hepatitis C
Hepatitis C
0.100 GeneticVariation BEFREE Five hundred and fifty-six HCV G2/3 patients (G2 n = 60; G3 n = 496) were treated with PEG-IFN alfa-2a 180 μg/week or PEG-IFN alfa-2b 1.5 μg/kg, + RBV 13.6 ± 2.3 (mean ± SD) mg/kg/day for median 47 (26-54) weeks. 25041136

2015

Entrez Id: 3439
Gene Symbol: IFNA1
IFNA1
CUI: C0019196
Disease: Hepatitis C
Hepatitis C
0.100 Biomarker BEFREE We identified all HIV/HCV co-infected patients who received anti-viral treatment with PEG-IFN and ribavirin in the Veterans Affairs healthcare system nationally between 2002 and 2009 (n = 665). 24127691

2013

Entrez Id: 3439
Gene Symbol: IFNA1
IFNA1
CUI: C0019196
Disease: Hepatitis C
Hepatitis C
0.100 GeneticVariation BEFREE The rs8099917 genotype and total PEG-IFN dose were associated with SVR in patients with hepatitis C virus genotype 1. 22156487

2011

Entrez Id: 3439
Gene Symbol: IFNA1
IFNA1
CUI: C0019196
Disease: Hepatitis C
Hepatitis C
0.100 Biomarker BEFREE The results of this study suggest a potential benefit for PEG-IFN and RBV combination therapy in maximizing virological responses in HCV/HIV participants with recent HCV, particularly those with a longer duration of HCV infection and unfavourable IL28B genotypes. 22555168

2012

Entrez Id: 3439
Gene Symbol: IFNA1
IFNA1
CUI: C0019196
Disease: Hepatitis C
Hepatitis C
0.100 Biomarker BEFREE Genetic diversity and response to IFN of the NS3 protease gene from clinical strains of the hepatitis C virus. 12111414

2002

Entrez Id: 3439
Gene Symbol: IFNA1
IFNA1
CUI: C0019196
Disease: Hepatitis C
Hepatitis C
0.100 AlteredExpression BEFREE As a result of IFN therapy HCV RNA and C5b-9 levels significantly decreased. 11099064

2000

Entrez Id: 3439
Gene Symbol: IFNA1
IFNA1
CUI: C0019196
Disease: Hepatitis C
Hepatitis C
0.100 Biomarker BEFREE Peg-IFN-based therapy in chronic HCV patients that resulted in SVR significantly decreased the risk of developing DM2 and independently predicts the development of new onset disease after controlling for correlates of metabolic syndrome. 28232517

2017

Entrez Id: 3439
Gene Symbol: IFNA1
IFNA1
CUI: C0019196
Disease: Hepatitis C
Hepatitis C
0.100 GeneticVariation BEFREE IL28B rs8099917/rs12979860 is useful in the treatment of MC-positive HCV patients with PEG-IFN and ribavirin; the TT/CC genotype is associated with SVR, the TG/TC with non-SVR; TT/CC is also predictive of MC in HCV patients. 26060059

2015

Entrez Id: 3439
Gene Symbol: IFNA1
IFNA1
CUI: C0019196
Disease: Hepatitis C
Hepatitis C
0.100 Biomarker BEFREE Our results demonstrated that ISG15 impairs HCV RNA replication in both the presence and absence of IFN stimulation, consistent with an antiviral role for ISG15 during HCV infection. 26361997

2015

Entrez Id: 3439
Gene Symbol: IFNA1
IFNA1
CUI: C0019196
Disease: Hepatitis C
Hepatitis C
0.100 Biomarker BEFREE In summary, intrahepatic expression of IFNL4 was associated with increased antiviral ISG expression and decreased suppressive ISG expression at baseline, resulting in poor responsiveness to IFNα-based therapy in HCV infection. 28036111

2017